Boehringer Ingelheim - Schizophrenia
Boehringer Ingelheim GmbH (“Boehringer Ingelheim”), founded in 1885, is one of the world’s 20 leading pharmaceutical companies. The focus of the family-owned company is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
In August 2016, Saniona and Boehringer Ingelheim entered into a research collaboration with the objective to discover and develop novel compounds for the treatment of schizophrenia. Saniona will receive research funding during the joint research period and up to €90 million in milestone payments including an upfront payment of €5 million upon signing of the agreement. Furthermore, Saniona is eligible to receive royalties on worldwide net sales of any resulting products under the collaboration. Saniona grants Boehringer Ingelheim exclusive worldwide rights to research, develop, manufacture and commercialize medicines identified through the collaboration.